Customize your JAMA Network experience by selecting one or more topics from the list below.
To assess whether routinely used cardiovascular disease (CVD) risk prediction scores can be improved by replacing or supplementing traditional cholesterol measurements with emerging lipid-related markers, investigators from the Emerging Risk Factors Collaboration analyzed data from 165 544 individuals (37 prospective cohort studies) who did not have CVD at baseline. Among the study findings were that the addition of information on the combination of apolipoprotein B and A-I, lipoprotein A, or lipoprotein-associated phospholipase A2 mass to risk scores containing total cholesterol and high-density lipoprotein cholesterol resulted in slight improvement in CVD risk prediction. In an editorial, Grundy discusses lipoprotein measures and CVD risk prediction.
This Week in JAMA. JAMA. 2012;307(23):2461. doi:10.1001/jama.2012.3048
Create a personal account or sign in to: